Stoic VC

Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.

Lenexa Medical specializes in developing innovative technology aimed at preventing pressure injuries in hospitalized patients. Their core product is a medical-grade smart sheet, an ultra-thin fabric bedsheet equipped with advanced sensing capabilities. This sheet, when used in conjunction with Lenexa's proprietary software, continuously monitors patient position and posture, thereby assessing the risk of pressure injuries. The company's services focus on providing clinicians with actionable insights to deliver targeted, long-term solutions for pressure injury detection and prevention, ultimately enhancing patient health outcomes.

BioScout is a technology company that focuses on detecting and preventing airborne diseases in agricultural settings. It has developed an integrated hardware and software platform specifically designed for farm fields. This patented system employs a combination of air sampling, mapping, and data analytics, utilizing sensors strategically placed throughout the fields. These sensors collect crucial data, which is then relayed to a disease dashboard, providing real-time information and text message alerts regarding high threat levels. By offering proactive disease management solutions, BioScout enables farmers to enhance crop yield and quality, improve spray efficiency, and effectively monitor the spread of diseases.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Wildlife Drones Pty. Ltd., founded in 2016 and based in Macquarie, Australia, specializes in designing and developing advanced animal radio-tracking systems utilizing drone technology. The company addresses the challenges faced by wildlife researchers in tracking the movements of radio-tagged animals, a process that can often be labor-intensive and costly when relying on traditional ground methods. By leveraging drones, Wildlife Drones enhances the quality and quantity of radio-tracking data collected, allowing for improved monitoring of endangered species, tracking of invasive species, and management of livestock in remote areas. This innovative approach provides wildlife researchers, conservationists, and environmental consultants with more effective tools to understand animal movements and minimize environmental impact.

OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.

Morse Micro is a wireless integrated circuit solutions company focused on advancing Wi-Fi technology for the Internet of Things (IoT). Founded by industry experts, including original Wi-Fi inventor Prof. Neil Weste, the company has a strong foundation in wireless innovation. Headquartered in Australia, with additional offices in China and the U.S., Morse Micro develops low-power Wi-Fi chips that facilitate connectivity across a wide array of IoT applications, such as surveillance systems, access control, industrial automation, and mobile devices. The company’s expertise and extensive portfolio of intellectual property enable it to create smaller and more cost-effective solutions for clients in the IoT market, enhancing the reach and efficiency of connected devices.

Agerris Pty Ltd, established in 2005 and based in Chippendale, Australia, specializes in designing and manufacturing modular robotics for the agricultural industry. The company's flagship product, Swagbot, is a modular robot that autonomously monitors and addresses weed issues, detects food, herds livestock, and assesses crops using computer vision. Additionally, Agerris develops an AI-based platform, Digital Farmhand, which enables farm machinery to detect and assess weeds, count individual fruit, nuts, crops, and animals. The company's products cater to various applications, including tree crop and row crop automation, intelligent spraying, livestock monitoring, and fruit and crop detection.

Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in the manufacture of smart helmets designed to enhance motorcycle safety. The helmets incorporate advanced features such as an integrated camera system, navigation, intercom capabilities, and active noise-cancelling technology. Recognizing the inherent dangers of motorcycling, Forcite aims to significantly improve safety for riders by integrating sensor technology and a proprietary software platform called Forcite Command. By utilizing lightweight carbon fiber in their helmet designs, the company seeks to provide a disruptive solution that addresses the lack of standard safety equipment in motorcycles, ultimately making riding safer and more enjoyable.

PERKii is a producer of innovative probiotic beverages designed to deliver live and protected probiotics in a refreshing, water-based drink. Each serving contains only 26 calories and minimal sugar, making it a healthier choice for consumers. Utilizing Progel™ technology, developed by scientists at The University of Queensland, PERKii encapsulates probiotics in microgels that withstand stomach acid, ensuring their effectiveness in promoting gut health and immunity. This unique technology sets PERKii apart from traditional probiotic drinks, enhancing the overall health benefits while providing a delicious taste experience. The company aims to support consumers in managing weight and improving their overall well-being through its carefully crafted beverages.

Exonate Limited is a privately held biotech company founded in 2013 and based in Duxford, United Kingdom, with a research and development laboratory in Nottingham. The company specializes in the discovery and development of small molecule drugs that target alternative messenger RNA splicing, particularly in the field of ophthalmology. Exonate's lead program focuses on diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD), significant causes of vision loss. The company has developed a pipeline of novel small molecule inhibitors, known as SPHINXes, which selectively inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the modulation of serine/threonine-protein kinase 1 (SRPK1)-mediated splicing. These inhibitors have shown promising efficacy in preclinical models as topical agents for treating these retinal disorders. Exonate is backed by a strong scientific foundation and leadership team, with connections to academic expertise at the University of Nottingham. The company is advancing its drug candidates through regulatory studies aimed at clinical evaluation.

Q-Sera Pty Ltd is an Australian biotechnology company that specializes in the development of advanced blood collection tubes utilizing the coagulant properties of snake venom-derived proteins. The company has harnessed the potent clotting capabilities of components found in snake venom, particularly from species like the Australian Taipan, to create blood collection tubes that enable rapid production of high-quality serum. This innovative technology enhances laboratory efficiency, clinical diagnosis, and patient care by facilitating quicker coagulation of blood samples. Q-Sera's products are manufactured using modified cell lines and standard pharmaceutical processes, ensuring reliability and effectiveness in biochemical analysis of blood samples. The company's focus on leveraging unique natural resources positions it at the forefront of advancements in clinical and laboratory practices.

Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.

Nexgen Plants is an innovative plant trait company focused on developing non-genetically modified (non-GM) solutions to enhance agricultural productivity and resilience against various challenges. The company specializes in creating disease-resistant plant breeds by leveraging a proprietary transformation technique that identifies key elements in native DNA. This approach enables the development of crops that are resistant to viruses and fungi, as well as traits such as salt tolerance and increased anthocyanin content. Nexgen Plants aims to produce the next generation of globally valued crops for food, fiber, energy, and ornamental purposes, ultimately helping agriculture-dependent communities improve their returns and adapt to emerging opportunities.

Certa is a technology company that specializes in managing third-party relationships for businesses. Its core product is an automated SaaS platform designed to streamline various aspects of third-party lifecycle management, including onboarding, due diligence, risk mitigation, and ongoing monitoring. This platform enables companies to efficiently manage the operational risks, compliance issues, and overall workflow associated with their third-party interactions globally from a single location.

Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.

Cardihab Pty Ltd., established in 2016 and based in Fortitude Valley, Australia, specializes in digital cardiac rehabilitation solutions. It offers a cloud-based portal and smartphone app, enabling clinicians to manage patient data, track goals, and connect to sensors. This allows for remote cardiac rehabilitation, reducing the need for frequent clinic visits and making the process more convenient and flexible for patients.

QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.

Smart Sparrow is an e-learning platform that facilitates the creation of interactive and adaptive courseware for a variety of subjects, including digital literacy, computer sciences, finance, and soft skills. Founded in 2010 by Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson, the company is headquartered in Surry Hills, Australia, with an additional office in San Francisco, California. Smart Sparrow's platform features a dynamic, drag-and-drop authoring tool compatible with any web browser, allowing educators to design personalized learning experiences. This tool enables real-time collaboration and provides access to pre-made templates, streamlining the course creation process. The company serves a diverse range of institutions both locally and internationally.